dievini Hopp Biotech Holding

Novaliq is a pharmaceutical company focused on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol, the first water-free technology for ophthalmology. The company targets dry eye disease with two complementary EyeSol-based approaches: NOV03, a perfluorohexyloctane formulation for evaporative dry eye associated with Meibomian gland dysfunction, and CyclASol, an ophthalmic solution of cyclosporine A in EyeSol for aqueous-deficient dry eye. It also commercializes NovaTears, water-free eye drops that stabilize the tear film, with NovaTears+Omega aiming to further reduce tear evaporation. Novaliq is headquartered in Heidelberg, Germany, with an office in Cambridge, United States. The portfolio addresses unmet medical needs in eye diseases and leverages EyeSol to deliver potent, well-tolerated therapies with a rapid onset of action.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, that specializes in oncology, focusing on the development of antibody drug conjugates (ADCs) using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. The company is advancing several therapeutic candidates, including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Heidelberg Pharma is also engaged in the development of MGTA-XX-ATACs for hematopoietic stem cells and conditioning programs for blood cancers and genetic diseases. In addition to its therapeutic development, the company provides preclinical research services in oncology, as well as inflammatory and autoimmune diseases, offering expertise in pharmacology, drug metabolism, and molecular biology. Established in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG has evolved into a significant player in the biopharmaceutical sector.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, that specializes in oncology, focusing on the development of antibody drug conjugates (ADCs) using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. The company is advancing several therapeutic candidates, including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Heidelberg Pharma is also engaged in the development of MGTA-XX-ATACs for hematopoietic stem cells and conditioning programs for blood cancers and genetic diseases. In addition to its therapeutic development, the company provides preclinical research services in oncology, as well as inflammatory and autoimmune diseases, offering expertise in pharmacology, drug metabolism, and molecular biology. Established in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG has evolved into a significant player in the biopharmaceutical sector.

Novaliq is a pharmaceutical company focused on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol, the first water-free technology for ophthalmology. The company targets dry eye disease with two complementary EyeSol-based approaches: NOV03, a perfluorohexyloctane formulation for evaporative dry eye associated with Meibomian gland dysfunction, and CyclASol, an ophthalmic solution of cyclosporine A in EyeSol for aqueous-deficient dry eye. It also commercializes NovaTears, water-free eye drops that stabilize the tear film, with NovaTears+Omega aiming to further reduce tear evaporation. Novaliq is headquartered in Heidelberg, Germany, with an office in Cambridge, United States. The portfolio addresses unmet medical needs in eye diseases and leverages EyeSol to deliver potent, well-tolerated therapies with a rapid onset of action.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Molecular Health is a computational biomedicine company that develops software systems to perform integrated analyses of clinical and genetic patient data to support treatment decisions. Its cloud-based Dataome platform analyzes molecular and clinical data against a broad body of medical, biological, and pharmacological knowledge to enable precise diagnostic, therapeutic, and drug safety decisions. The company offers SafetyMAP for de-risking and safety analysis in drug research for regulators and the pharmaceutical and health insurance sectors; InsightMAP providing professional research services and custom solutions for drug discovery and development; and TreatmentMAP, a medical device that generates individualized tumor analyses and clinical interpretations for evidence-based targeted therapy. Founded in 2004 and based in Heidelberg, Germany, it maintains a subsidiary in Cambridge, Massachusetts, and an office in Berlin. It originated as Life Biosystems AG and adopted Molecular Health in 2011. Investors include Dievini Hopp BioTech.

CureVac is a biopharmaceutical company developing transformative medicines using messenger RNA (mRNA). Its product pipeline includes cancer immunotherapies, prophylactic vaccines against infectious diseases, molecular therapies for various indications, and mRNA-encoded antibodies.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

AC Immune is a Swiss-based biopharmaceutical company focused on developing therapies for neurodegenerative diseases associated with protein misfolding. It uses its proprietary platforms to create antibodies, small molecules, and vaccines targeting various neurodegenerative indications.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Novaliq is a pharmaceutical company focused on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol, the first water-free technology for ophthalmology. The company targets dry eye disease with two complementary EyeSol-based approaches: NOV03, a perfluorohexyloctane formulation for evaporative dry eye associated with Meibomian gland dysfunction, and CyclASol, an ophthalmic solution of cyclosporine A in EyeSol for aqueous-deficient dry eye. It also commercializes NovaTears, water-free eye drops that stabilize the tear film, with NovaTears+Omega aiming to further reduce tear evaporation. Novaliq is headquartered in Heidelberg, Germany, with an office in Cambridge, United States. The portfolio addresses unmet medical needs in eye diseases and leverages EyeSol to deliver potent, well-tolerated therapies with a rapid onset of action.

CureVac is a biopharmaceutical company developing transformative medicines using messenger RNA (mRNA). Its product pipeline includes cancer immunotherapies, prophylactic vaccines against infectious diseases, molecular therapies for various indications, and mRNA-encoded antibodies.

Novaliq is a pharmaceutical company focused on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol, the first water-free technology for ophthalmology. The company targets dry eye disease with two complementary EyeSol-based approaches: NOV03, a perfluorohexyloctane formulation for evaporative dry eye associated with Meibomian gland dysfunction, and CyclASol, an ophthalmic solution of cyclosporine A in EyeSol for aqueous-deficient dry eye. It also commercializes NovaTears, water-free eye drops that stabilize the tear film, with NovaTears+Omega aiming to further reduce tear evaporation. Novaliq is headquartered in Heidelberg, Germany, with an office in Cambridge, United States. The portfolio addresses unmet medical needs in eye diseases and leverages EyeSol to deliver potent, well-tolerated therapies with a rapid onset of action.

Apogenix is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics for cancer treatment. Its lead product, Asunercept, targets glioblastoma and myelodysplastic syndromes. The company's HERA-ligand technology platform constructs novel TNFSF receptor agonists for cancer therapy.

Novaliq is a pharmaceutical company focused on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol, the first water-free technology for ophthalmology. The company targets dry eye disease with two complementary EyeSol-based approaches: NOV03, a perfluorohexyloctane formulation for evaporative dry eye associated with Meibomian gland dysfunction, and CyclASol, an ophthalmic solution of cyclosporine A in EyeSol for aqueous-deficient dry eye. It also commercializes NovaTears, water-free eye drops that stabilize the tear film, with NovaTears+Omega aiming to further reduce tear evaporation. Novaliq is headquartered in Heidelberg, Germany, with an office in Cambridge, United States. The portfolio addresses unmet medical needs in eye diseases and leverages EyeSol to deliver potent, well-tolerated therapies with a rapid onset of action.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

CureVac is a biopharmaceutical company developing transformative medicines using messenger RNA (mRNA). Its product pipeline includes cancer immunotherapies, prophylactic vaccines against infectious diseases, molecular therapies for various indications, and mRNA-encoded antibodies.

Apogenix is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics for cancer treatment. Its lead product, Asunercept, targets glioblastoma and myelodysplastic syndromes. The company's HERA-ligand technology platform constructs novel TNFSF receptor agonists for cancer therapy.